Exosomes injection on poor responder ovary
Phase 2
- Conditions
- Poor ovarian response.Female infertility of other originN97.8
- Registration Number
- IRCT20091012002576N37
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Abnormal ovarian reserve test
Antral follicle count <5
At least one previous IVF cycle <3 oocyte was retrieved.
Exclusion Criteria
Ovarian insufficiency due to gonadal dysgenesia and abnormality of chromosoms
Male infertility
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AMH. Timepoint: Three months after intervention. Method of measurement: Blood test.;FSH. Timepoint: Three months after intervention. Method of measurement: Blood test.;Number of oocyte. Timepoint: Three months after intervention. Method of measurement: Follicle counts in transvaginal sonogram.
- Secondary Outcome Measures
Name Time Method Biochemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: ?BhCG measurement.;Clinical pregnancy. Timepoint: Four weeks after embryo transfer. Method of measurement: Fetal heart activity in transvaginal sonogram.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways do MSC-derived exosomes target to improve ovarian response in infertility?
How does intraovarian exosome therapy compare to standard gonadotropin protocols in poor responders?
Which biomarkers predict response to MSC-exosome treatment in women with diminished ovarian reserve?
What are the safety profiles and adverse event management strategies for exosome-based ovarian rejuvenation?
Are there synergistic effects when combining MSC-exosome therapy with growth hormone in poor ovarian responders?